



Re: Signing an agreement for the manufacturing and marketing of Lipicare (subsidiary) Ocular D product

BioLight (“The Company”) hereby announces that on July 28, 2021, its subsidiary company, Lipicare Pharmaceuticals Ltd. (“Lipicare”), has entered into an agreement (“Agreement”) with SIFI S.p.A, a leading ophthalmic company headquartered in Italy (“SIFI”), to manufacture Lipicare’s “Ocular D” Product (“Product”), by SIFI, for its marketing and distribution exclusively by Lipicare in Europe and in countries where CE approval is accepted. As reported to the Company, in May 2021 the Product received marketing approval in Europe (CE approval) as part of SIFI's registration file.

The Ocular D product is a proprietary nano emulsion formulation combined with vitamin D. As reported to the Company, Lipicare has carried out a number of laboratory experiments that have shown that the Product helps filter blue light absorption and thus may provide additional eye protection for a syndrome known as digital eye strain and other uses, in addition to its potential benefits for dry eye symptoms. As reported to the Company, blue light filtration may help treat and relieve a syndrome called digital eye strain which is characterized by eye fatigue and dryness resulting from exposure for long hours to blue light radiation from computer screens. Lipicare sees this as an opportunity to try and shape a new market segment (about 50% of the population using computers in the US reports digital eye strain), in addition to the dry eye care market.

The term of the Agreement with SIFI is effective for ten years (subject to renewal of the CE approval, as required by December 2022), and includes, inter alia, commitments for the production by SIFI, purchase and distribution by Lipicare of the Product according to the agreed price which decreases as manufacturing of the Product volume is increased.



Upon signing the Agreement, Lipicare is working towards building a marketing infrastructure for the Product, mainly through sub-distributors, and has already begun recruiting experts in this field, and expects to launch the Ocular D product by end of 2022.

About Lipicare

LipiCare Pharmaceuticals is currently focused on commercializing the Ocular D Product and thereafter intends to develop its nano emulsion based platform technology.

About SIFI

SIFI is a leading international ophthalmic company headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures, and markets innovative therapeutic solutions for patients with ophthalmic conditions. SIFI is fully committed through its R&D to improve patients' quality of life, exporting treatments to more than 20 countries worldwide with a direct presence in Italy, Spain, France, Romania, Mexico, and Turkey. Since June 2015, SIFI is backed by the private equity 21 Invest to support the company's international expansion and portfolio development strategy. More information available at www.sifigroup.com

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies. The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.